Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Cassidy Henegar"'
Autor:
Cassidy Henegar, Emilio Letang, Ruolan Wang, Charles Hicks, Dainielle Fox, Bryn Jones, Annemiek de Ruiter, Vani Vannappagari
Publikováno v:
Viruses, Vol 15, Iss 12, p 2426 (2023)
After a decade of dolutegravir (DTG) use in various antiretroviral therapy combinations and in diverse populations globally, it is critical to identify HIV strains with reduced drug susceptibility and monitor emergent resistance in people living with
Externí odkaz:
https://doaj.org/article/5e4258e6fd074057a87d7196a6010221
Autor:
Lei Yan, Cassidy Henegar, Kirsha Gordon, Charles Hicks, Vani Vannappagari, Amy C Justice, Mihaela Aslan
Publikováno v:
Open Forum Infectious Diseases. 9
Background HIV management among older people living with HIV (PLWH) may be complicated by the presence of multiple comorbidities and polypharmacy. This study evaluated effectiveness and durability of modern 3-drug antiretroviral regimens among older
Autor:
Ricky K Hsu, Laurence Brunet, Jennifer S Fusco, Cassidy Henegar, Vani Vannappagari, Andrew Clark, Philip C Lackey, Gerald Pierone, Gregory P Fusco
Publikováno v:
Open Forum Infectious Diseases. 9
Background Paired with other active antiretrovirals (ARVs), fostemsavir (FTR) may offer heavily treatment-experienced (HTE) people with HIV (PWH) options for continuing effective treatment. Durability and effectiveness of FTR-containing regimens in r
Autor:
Gerald Pierone, Jennifer S Fusco, Laurence Brunet, Vani Vannappagari, Supriya Sarkar, Cassidy Henegar, Jean A van Wyk, Andrew Zolopa, Gregory P Fusco
Publikováno v:
Open Forum Infectious Diseases. 9
Background Real-world effectiveness of fixed dose dolutegravir/lamivudine (DTG/3TC) two-drug regimens (2DR) during the first 24 months of availability in the US was compared to common three-drug regimens (3DRs) among suppressed antiretroviral therapy
Autor:
Jennifer S Fusco, Laurence Brunet, Vani Vannappagari, Melissa Crawford, Ricky Hsu, Jean van Wyk, Gregory Fusco, Karam Mounzer, Janet Lo, Cassidy Henegar
Publikováno v:
AIDS Research and Human Retroviruses. 37:852-861
With obesity on the rise among people living with HIV (PLWH), there is growing concern that weight gain may result as an undesired effect of antiretroviral therapy (ART). This analysis sought to assess the association between ART regimens and changes
Autor:
Amanda L. Willig, Jean van Wyk, B Rodriguez, Cassidy Henegar, Ann C. Collier, Bridget M. Whitney, Barbara N Harding, Joseph J. Eron, Mari M. Kitahata, Stephanie A. Ruderman, William C. Mathews, Michael S. Saag, Vani Vannappagari, Joseph A.C. Delaney, Elvin Geng, Sara Lindström, Lloyd Curtis, Richard D. Moore, Greer A Burkholder, Robin M. Nance, Kenneth H. Mayer, Brian R. Wood, Heidi M. Crane
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 86:339-343
Objectives Evaluate differences in weight change by regimen among people living with HIV (PLWH) initiating antiretroviral therapy (ART) in the current era. Methods Between 2012 and 2019, 3232 ART-naive PLWH initiated ≥3-drug ART regimens in 8 Cente
Autor:
Karam Mounzer, Jean van Wyk, Vani Vannappagari, Ricky Hsu, Gregory Fusco, Lloyd Curtis, Jennifer S Fusco, Cassidy Henegar, Janet Lo, Laurence Brunet
Publikováno v:
AIDS. 35:81-90
Objectives To describe the prevalence and incidence of prediabetes and type 2 diabetes mellitus (T2DM) among people living with HIV (PLHIV) and evaluate the association between antiretroviral therapy (ART) initiation with dolutegravir (DTG), elvitegr
Autor:
Cassidy Henegar, Gregory Fusco, Kimberly Y. Smith, Jennifer S Fusco, Michael Aboud, Evelyn Byrd Quinlivan, Vani Vannappagari
Publikováno v:
Current HIV Research. 17:266-276
Background:Women face unique complexities in HIV treatment yet are underrepresented in antiretroviral therapy (ART) studies.Objective:This analysis assessed the one-year durability of the first integrase strand transfer inhibitor (INSTI)-based regime
Autor:
R Hsu, Jennifer S Fusco, Vani Vannappagari, Karam Mounzer, Cassidy Henegar, Gregory Fusco, Mark S. Shaefer, Chris M. Stainsby, Leigh Ragone, Laurence Brunet
Publikováno v:
AIDS Research and Therapy, Vol 16, Iss 1, Pp 1-9 (2019)
Background HLA-B*57:01 screening was added to clinical care guidelines in 2008 to reduce the risk of hypersensitivity reaction from abacavir. The uptake of HLA-B*57:01 screening and incidence of hypersensitivity reaction were assessed in a prospectiv
Autor:
Lindsay M. Carter, Cassidy Henegar, Charlotte E. Lane, Teodora Perger, Vani Vannappagari, Karam Mounzer, Rimgaile Urbaityte, Mark S. Shaefer, C. Stainsby, James Oyee, Gary E. Pakes, Ricky Hsu
Publikováno v:
Pharmacotherapy
Introduction Human leukocyte antigen (HLA)‐B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening was adopted in GlaxoSmithKline and ViiV Healthcare clinical trials in 2007 and human imm